US FDA OK's Gilead's Truvada as 1st HIV prophylaxis pill
This article was originally published in Scrip
Gilead Sciences won approval to expand the indication for Truvada (emtricitabine/tenofovir disoproxil fumarate) in the US as the first agent prescribed as a pre-exposure prophylaxis (PrEP) therapy to reduce the risk of HIV-1 among uninfected adults at high risk of acquiring the infection – gaining the US FDA's nod amid controversy.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.